# Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma

> **NCT07028125** · PHASE4 · RECRUITING · sponsor: **Centre Francois Baclesse** · enrollment: 83 (estimated)

## Conditions studied

- Renal Cell Carcinoma (Kidney Cancer)
- Metastatic Renal Cell Carcinoma
- Locally Advanced

## Interventions

- **DRUG:** cabozantinib and nivolumab

## Key facts

- **NCT ID:** NCT07028125
- **Lead sponsor:** Centre Francois Baclesse
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-01
- **Primary completion:** 2028-10
- **Final completion:** 2029-01
- **Target enrollment:** 83 (ESTIMATED)
- **Last updated:** 2025-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07028125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07028125, "Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07028125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*